SG11201903182XA - 6,7,8,9-tetrahydro-3h-pyrazolo[4,3-f]isoquinoline derivatives useful in the treatment of cancer - Google Patents
6,7,8,9-tetrahydro-3h-pyrazolo[4,3-f]isoquinoline derivatives useful in the treatment of cancerInfo
- Publication number
- SG11201903182XA SG11201903182XA SG11201903182XA SG11201903182XA SG11201903182XA SG 11201903182X A SG11201903182X A SG 11201903182XA SG 11201903182X A SG11201903182X A SG 11201903182XA SG 11201903182X A SG11201903182X A SG 11201903182XA SG 11201903182X A SG11201903182X A SG 11201903182XA
- Authority
- SG
- Singapore
- Prior art keywords
- cambridge
- building
- astrazeneca
- owg
- darwin
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Lin (CouNR? ° 8000 6000 4000 2000 W O 20 18/077 630 Al (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 03 May 2018 (03.05.2018) WIPO I PCT ~~ll~~~~~~~~ 011101110VIIIOH olo olomo milo111110 Elio ow (10) International Publication Number WO 2018/077630 Al L 10 (51) International Patent Classification: CO7D 471/04 (2006.01) A61K 31/497 (2006.01) A61K 31/4738 (2006.01) A61P 35/00 (2006.01) (21) International Application Number: PCT/EP2017/076191 (22) International Filing Date: 13 October 2017 (13.10.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/411,799 24 October 2016 (24.10.2016) US 62/435,159 16 December 2016 (16.12.2016) US (71) Applicant: ASTRAZENECA AB [SE/SE]; SE-151 85 Sodertalje (SE). (72) Inventors: SCOTT, James, Stewart; AstraZeneca Dar- win Building, Cambridge Science Park, Milton Road Cambridge CB4 OWG (GB). BARLAAM, Bernard, Christophe; AstraZeneca, Darwin Building Cambridge Science Park, Milton Road, Cambridge Cambridgeshire CB4 OWG (GB). YANG, Bin; AstraZeneca 35 Gatehouse Drive, Waltham, MA 02451 (US). MOSS, Thomas, An- drew; AstraZeneca, Darwin Building Darwin Building, Cambridge Science Park, Milton Road Cambridgeshire CB4 OWG (GB). HUGHES, Samantha, Jayne; As- traZeneca Darwin Building, Cambridge Science Park, Milton Road, Cambridge Cambridgeshire CB4 OWG (GB). NISSINK, Johannes, Wilhelmus, Maria; As- traZeneca, Darwin Building Cambridge Science Park, Mil- ton Road, Cambridge Canbridgeshire CB4 OWG (GB). O'DONOVAN, Daniel, Hillebrand; AstraZeneca Darwin Building, Cambridge Science Park, Milton Road, Cam- bridge Cambridgeshire CB4 OWG (GB). (74) Agent: COOK, Andrew, James; AstraZeneca Milstein Building, Cambridge Cambridgeshire CB21 6GH (GB). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. = (54) Title: 6,7,8,9-TETRAHYDRO-3H-PYRAZOLO[4,3-F]ISOQUINOLINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER (57) : The specification relates to compounds of Formula (I) and to pharmaceutically acceptable salts thereof, to processes and intermedi- ates used for their preparation, to pharmaceutical compositions containing them and to their use in the treatment of cell proliferative disorders. (I) Figure 1: X-Ray Ponder Diffraction Pattern for Form A of 13-043- finoropropyhamtiffin 3 yl) 6 ((6S,8R) 8 methyl 7 (2,2,2 trifluoroethyl)-6,7,8.8- lelrahydro-311-pyrazoloi4,3-flisoquinolin-6-ylipyridin-3-amine 16000 14000 20 2-Theta - Scale [Continued on next page] WO 2018/077630 Al IMEDIMOM0101011MERI00 IIEMEHIIIIHMEDIMIE (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) Published: — with international search report (Art. 21(3))
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662411799P | 2016-10-24 | 2016-10-24 | |
| US201662435159P | 2016-12-16 | 2016-12-16 | |
| PCT/EP2017/076191 WO2018077630A1 (en) | 2016-10-24 | 2017-10-13 | 6,7,8,9-tetrahydro-3h-pyrazolo[4,3-f]isoquinoline derivatives useful in the treatment of cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201903182XA true SG11201903182XA (en) | 2019-05-30 |
Family
ID=60083331
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201903182XA SG11201903182XA (en) | 2016-10-24 | 2017-10-13 | 6,7,8,9-tetrahydro-3h-pyrazolo[4,3-f]isoquinoline derivatives useful in the treatment of cancer |
Country Status (36)
| Country | Link |
|---|---|
| US (4) | US10131663B2 (en) |
| EP (2) | EP3433256B1 (en) |
| JP (2) | JP6744489B2 (en) |
| KR (1) | KR102178692B1 (en) |
| CN (2) | CN114656464B (en) |
| AU (1) | AU2017349797B2 (en) |
| BR (1) | BR112019007393A2 (en) |
| CA (1) | CA3040040A1 (en) |
| CL (1) | CL2019001077A1 (en) |
| CO (1) | CO2019003950A2 (en) |
| CR (1) | CR20190204A (en) |
| CY (2) | CY1122566T1 (en) |
| DK (2) | DK3433256T3 (en) |
| DO (1) | DOP2019000104A (en) |
| EC (1) | ECSP19028657A (en) |
| ES (2) | ES2751902T3 (en) |
| HR (1) | HRP20220255T1 (en) |
| HU (2) | HUE057524T2 (en) |
| IL (1) | IL266245B (en) |
| JO (1) | JOP20190090B1 (en) |
| LT (2) | LT3640251T (en) |
| ME (1) | ME03547B (en) |
| MX (1) | MX2019004685A (en) |
| NI (1) | NI201900039A (en) |
| NZ (1) | NZ753459A (en) |
| PE (1) | PE20191078A1 (en) |
| PH (1) | PH12019500830A1 (en) |
| PL (2) | PL3433256T3 (en) |
| PT (2) | PT3433256T (en) |
| RS (1) | RS59445B1 (en) |
| SG (1) | SG11201903182XA (en) |
| SI (2) | SI3640251T1 (en) |
| TW (1) | TWI735681B (en) |
| UA (1) | UA125824C2 (en) |
| WO (1) | WO2018077630A1 (en) |
| ZA (1) | ZA201900694B (en) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10292971B2 (en) | 2015-10-01 | 2019-05-21 | Olema Pharmaceuticals, Inc. | Tetrahydro-1H-pyrido[3,4-b]indole anti-estrogenic drugs |
| JP7241542B2 (en) * | 2016-04-08 | 2023-03-17 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | Tetrahydroisoquinoline estrogen receptor modulators and uses thereof |
| TW201803870A (en) | 2016-04-20 | 2018-02-01 | 阿斯特捷利康公司 | Chemical compounds |
| US10149839B2 (en) | 2016-07-25 | 2018-12-11 | Astrazeneca Ab | Chemical compounds |
| CN114656464B (en) * | 2016-10-24 | 2024-10-15 | 阿斯利康(瑞典)有限公司 | 6,7,8, 9-Tetrahydro-3H-pyrazolo [4,3-f ] isoquinoline derivatives useful in the treatment of cancer |
| JOP20190144A1 (en) | 2016-12-16 | 2019-06-16 | Janssen Pharmaceutica Nv | Imidazopyrrolopyridine as inhibitors of the jak family of kinases |
| TWI831738B (en) | 2016-12-16 | 2024-02-11 | 美商瑞塔醫藥有限責任公司 | PYRIMIDINE TRICYCLIC ENONE DERIVATIVES FOR INHIBITION OF RORγ AND OTHER USES |
| MY196260A (en) | 2016-12-16 | 2023-03-24 | Janssen Pharmaceutica Nv | Small Molecule Inhibitors of the Jak Family Of Kinases |
| PL3494116T3 (en) | 2017-01-30 | 2020-04-30 | Astrazeneca Ab | Estrogen receptor modulators |
| WO2019002442A1 (en) * | 2017-06-29 | 2019-01-03 | Astrazeneca Ab | Chemical compounds |
| WO2019002441A1 (en) * | 2017-06-29 | 2019-01-03 | Astrazeneca Ab | Chemical compounds |
| JP7113542B2 (en) * | 2017-11-14 | 2022-08-05 | カインド ファーマシューティカル | Heterocyclic compounds and their medical applications |
| TW202016110A (en) | 2018-06-15 | 2020-05-01 | 比利時商健生藥品公司 | Small molecule inhibitors of the jak family of kinases |
| EP3807265A1 (en) | 2018-06-15 | 2021-04-21 | Reata Pharmaceuticals, Inc. | Pyrazole and imidazole compounds for inhibition of il-17 and rorgamma |
| EP3810141A1 (en) | 2018-06-20 | 2021-04-28 | Reata Pharmaceuticals, Inc. | Cysteine-dependent inverse agonists of nuclear receptors ror-gamma/ror-gamma-t and methods of treating diseases or disorders therewith |
| US11081236B2 (en) | 2018-08-17 | 2021-08-03 | Genentech, Inc. | Diagnostic and therapeutic methods for the treatment of breast cancer |
| CN109053524A (en) * | 2018-09-11 | 2018-12-21 | 山东谛爱生物技术有限公司 | A kind of preparation method of N-Boc-3- hydroxy azetidine |
| JP2023522415A (en) * | 2020-04-24 | 2023-05-30 | アストラゼネカ・アクチエボラーグ | Dosing Regimens for Treatment of Cancer |
| CN115443128A (en) * | 2020-04-24 | 2022-12-06 | 阿斯利康(瑞典)有限公司 | Pharmaceutical formulations |
| CN115836068A (en) * | 2020-05-15 | 2023-03-21 | 先声药业有限公司 | Pyrrolidine compounds and application thereof |
| TW202214626A (en) * | 2020-06-12 | 2022-04-16 | 大陸商江蘇先聲藥業有限公司 | Estrogen receptor modulator compounds and use thereof |
| WO2022001971A1 (en) * | 2020-06-28 | 2022-01-06 | 南京明德新药研发有限公司 | Indazole-fused cyclic compound |
| CN114105977B (en) * | 2020-08-28 | 2023-09-01 | 先声再明医药有限公司 | Estrogen receptor modulator compounds and uses thereof |
| KR20220107752A (en) | 2021-01-26 | 2022-08-02 | 충북대학교 산학협력단 | Pyrazoloquinoline derivatives and their use as anticancer agents |
| CN116669729A (en) * | 2021-02-08 | 2023-08-29 | 贝达药业股份有限公司 | Heteroaryl piperidine derivative, and pharmaceutical composition and application thereof |
| EP4458821A1 (en) * | 2021-12-28 | 2024-11-06 | Shenzhen Vybio Pharmaceutical Technology Co., Ltd. | Salt form and crystal form of tetrahydrocyclohepta indazole compound |
| TW202430176A (en) | 2022-10-17 | 2024-08-01 | 瑞典商阿斯特捷利康公司 | Combination therapies for the treatment of cancer |
| WO2024100236A1 (en) | 2022-11-11 | 2024-05-16 | Astrazeneca Ab | Combination therapies for the treatment of cancer |
| US20240180893A1 (en) | 2022-11-17 | 2024-06-06 | Astrazeneca Ab | Methods of treatment of breast cancer |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| DK1320531T3 (en) | 2000-08-10 | 2011-01-03 | Pfizer Italia Srl | Bicyclo-pyrazoles active as kinase inhibitors, processes for their preparation and pharmaceutical compositions containing them |
| TW200716628A (en) | 2005-03-22 | 2007-05-01 | Astrazeneca Ab | Novel compounds |
| FR2884252B1 (en) | 2005-04-08 | 2007-05-18 | Aventis Pharma Sa | NOVEL ISOINDOLE DERIVATIVES, COMPOSITIONS CONTAINING SAME, PREPARATION THEREOF AND PHARMACEUTICAL USES THEREOF, IN PARTICULAR AS INHIBITORS OF CHAPERONE HSP90 PROTEIN ACTIVITY |
| AR058223A1 (en) | 2005-11-25 | 2008-01-23 | Palau Pharma Sa | A COMMITTEE OF PIRAZOLOISOQUINOLINE DERIVATIVES, A PROCEDURE FOR THE PREPARATION OF SUCH COMPOUND AND A PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUND |
| EP2223925A1 (en) | 2006-10-09 | 2010-09-01 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
| US20120157401A1 (en) | 2009-05-27 | 2012-06-21 | Ptc Therapeutics, Inc. | Methods for treating neurofibromatosis |
| WO2010138659A1 (en) | 2009-05-27 | 2010-12-02 | Ptc Therapeutics, Inc. | Methods for treating brain tumors |
| CN102480957A (en) | 2009-05-27 | 2012-05-30 | Ptc医疗公司 | Methods For Treating Cancer And Non-neoplastic Conditions |
| BR112012031464A2 (en) | 2010-06-10 | 2020-08-04 | Aragon Pharmaceuticals, Inc. | estrogen receptor modulators and their uses |
| WO2011159769A2 (en) | 2010-06-17 | 2011-12-22 | Aragon Pharmaceuticals, Inc. | Indane estrogen receptor modulators and uses thereof |
| AU2011347718B2 (en) * | 2010-12-24 | 2016-06-23 | Msd Oss B.V. | N-substituted azetidine derivatives |
| KR20140101399A (en) | 2011-12-14 | 2014-08-19 | 세라곤 파마슈티컬스, 인크. | Fluorinated estrogen receptor modulators and uses thereof |
| DK3004090T3 (en) | 2013-05-28 | 2018-01-08 | Astrazeneca Ab | CHEMICAL COMPOUNDS |
| PE20160157A1 (en) | 2013-06-19 | 2016-03-18 | Seragon Pharmaceuticals Inc | MODULATORS OF THE ESTROGEN RECEPTORS AND THEIR USES |
| KR20160021281A (en) | 2013-06-19 | 2016-02-24 | 세라곤 파마슈티컬스, 인크. | Azetidine estrogen receptor modulators and uses thereof |
| WO2015092634A1 (en) | 2013-12-16 | 2015-06-25 | Novartis Ag | 1,2,3,4-tetrahydroisoquinoline compounds and compositions as selective estrogen receptor antagonists and degraders |
| JP2017538727A (en) | 2014-12-18 | 2017-12-28 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | Derivatives of 2,3-diphenylchromene useful for the treatment of cancer |
| TWI699363B (en) | 2014-12-18 | 2020-07-21 | 瑞士商赫孚孟拉羅股份公司 | TETRAHYDRO-PYRIDO[3,4-b]INDOLE ESTROGEN RECEPTOR MODULATORS AND USES THEREOF |
| CN107406424B (en) | 2014-12-18 | 2020-08-25 | 豪夫迈·罗氏有限公司 | Estrogen receptor modulators and uses thereof |
| WO2016174551A1 (en) | 2015-04-27 | 2016-11-03 | Pfizer Inc. | Anti-estrogenic compounds |
| US10053451B2 (en) | 2015-05-26 | 2018-08-21 | Genentech, Inc. | Heterocyclic estrogen receptor modulators and uses thereof |
| CA2988620A1 (en) * | 2015-06-16 | 2016-12-22 | Jiangsu Hengrui Medicine Co., Ltd. | Piperidine derivative and preparation method and pharmaceutical use thereof |
| CN106518768B (en) | 2015-09-15 | 2021-07-02 | 江苏恒瑞医药股份有限公司 | Acrylic acid derivative, preparation method and medical application thereof |
| US10292971B2 (en) | 2015-10-01 | 2019-05-21 | Olema Pharmaceuticals, Inc. | Tetrahydro-1H-pyrido[3,4-b]indole anti-estrogenic drugs |
| US10399939B2 (en) | 2015-11-09 | 2019-09-03 | Genentech, Inc. | Tetrahydronaphthalene estrogen receptor modulators and uses thereof |
| KR102099159B1 (en) | 2015-11-12 | 2020-04-10 | 쯔지앙 하이썬 파머슈티컬 컴퍼니, 리미티드 | Acrylic acid derivatives, methods for their preparation and methods of use in medicine |
| US10398689B2 (en) | 2015-12-22 | 2019-09-03 | Jiangsu Hengrui Medicine Co., Ltd. | Benzopiperidine derivative, preparation method thereof and medical use thereof |
| JP7241542B2 (en) * | 2016-04-08 | 2023-03-17 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | Tetrahydroisoquinoline estrogen receptor modulators and uses thereof |
| WO2017182495A1 (en) * | 2016-04-20 | 2017-10-26 | Astrazeneca Ab | Indazole derivatives that down-regulate the estrogen receptor and possess anti-cancer activity |
| TW201803870A (en) * | 2016-04-20 | 2018-02-01 | 阿斯特捷利康公司 | Chemical compounds |
| JP7064772B2 (en) | 2016-05-06 | 2022-05-11 | ザビエル・ユニバーシティ・オブ・ルイジアナ | Selective Estrogen Receptor Down Regulator (SERDS) |
| CN109415361B (en) | 2016-06-29 | 2022-03-08 | 浙江海正药业股份有限公司 | Acrylic acid derivative, preparation method thereof and application thereof in medicine |
| US10149839B2 (en) | 2016-07-25 | 2018-12-11 | Astrazeneca Ab | Chemical compounds |
| CN107814798B (en) | 2016-09-14 | 2020-11-03 | 四川科伦博泰生物医药股份有限公司 | 3-substituted acrylic acid compound and preparation method and application thereof |
| ES2975558T3 (en) | 2016-09-15 | 2024-07-09 | Arvinas Inc | Indole derivatives as estrogen receptor degraders |
| CN114656464B (en) * | 2016-10-24 | 2024-10-15 | 阿斯利康(瑞典)有限公司 | 6,7,8, 9-Tetrahydro-3H-pyrazolo [4,3-f ] isoquinoline derivatives useful in the treatment of cancer |
| BR102016024814A2 (en) | 2016-10-24 | 2018-05-08 | Aché Laboratórios Farmacêuticos S.A. | Compound, Compounding Process, Pharmaceutical Composition, Compound Use, and Method of Treatment of Psychiatric Disorders and / or Sleep Disorders |
| MX2019007120A (en) | 2016-12-16 | 2019-09-16 | Basf Se | Pesticidal compounds. |
| MA53881A (en) | 2016-12-16 | 2022-04-27 | Lilly Co Eli | PYRIDO[4,3-D][1,3]OXAZIN-2-ONE DERIVATIVES AS INHIBITORS OF THE MUTED FORM OF IDH1 AND IDH2 PROTEINS |
| JOP20190144A1 (en) | 2016-12-16 | 2019-06-16 | Janssen Pharmaceutica Nv | Imidazopyrrolopyridine as inhibitors of the jak family of kinases |
| TWI831738B (en) | 2016-12-16 | 2024-02-11 | 美商瑞塔醫藥有限責任公司 | PYRIMIDINE TRICYCLIC ENONE DERIVATIVES FOR INHIBITION OF RORγ AND OTHER USES |
| MY196260A (en) | 2016-12-16 | 2023-03-24 | Janssen Pharmaceutica Nv | Small Molecule Inhibitors of the Jak Family Of Kinases |
| BR112019012211A2 (en) | 2016-12-16 | 2019-11-12 | Pfizer | glp-1 receptor agonists and uses thereof |
| EA039783B1 (en) | 2017-01-30 | 2022-03-14 | КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. | TYROSINE AMIDE DERIVATIVES AS Rho KINASE INHIBITORS |
-
2017
- 2017-10-13 CN CN202210381693.8A patent/CN114656464B/en active Active
- 2017-10-13 SI SI201731087T patent/SI3640251T1/en unknown
- 2017-10-13 HR HRP20220255TT patent/HRP20220255T1/en unknown
- 2017-10-13 PE PE2019000845A patent/PE20191078A1/en unknown
- 2017-10-13 JP JP2019520525A patent/JP6744489B2/en active Active
- 2017-10-13 HU HUE19189010A patent/HUE057524T2/en unknown
- 2017-10-13 WO PCT/EP2017/076191 patent/WO2018077630A1/en active Application Filing
- 2017-10-13 DK DK17783857T patent/DK3433256T3/en active
- 2017-10-13 LT LTEP19189010.2T patent/LT3640251T/en unknown
- 2017-10-13 CA CA3040040A patent/CA3040040A1/en active Pending
- 2017-10-13 PL PL17783857T patent/PL3433256T3/en unknown
- 2017-10-13 EP EP17783857.0A patent/EP3433256B1/en active Active
- 2017-10-13 NZ NZ753459A patent/NZ753459A/en unknown
- 2017-10-13 KR KR1020197014062A patent/KR102178692B1/en active IP Right Grant
- 2017-10-13 MX MX2019004685A patent/MX2019004685A/en unknown
- 2017-10-13 BR BR112019007393A patent/BR112019007393A2/en unknown
- 2017-10-13 HU HUE17783857A patent/HUE045714T2/en unknown
- 2017-10-13 ES ES17783857T patent/ES2751902T3/en active Active
- 2017-10-13 US US15/782,904 patent/US10131663B2/en active Active
- 2017-10-13 EP EP19189010.2A patent/EP3640251B1/en active Active
- 2017-10-13 JO JOP/2019/0090A patent/JOP20190090B1/en active
- 2017-10-13 AU AU2017349797A patent/AU2017349797B2/en active Active
- 2017-10-13 TW TW106135012A patent/TWI735681B/en active
- 2017-10-13 PT PT177838570T patent/PT3433256T/en unknown
- 2017-10-13 ES ES19189010T patent/ES2907759T3/en active Active
- 2017-10-13 ME MEP-2019-306A patent/ME03547B/en unknown
- 2017-10-13 RS RSP20191371 patent/RS59445B1/en unknown
- 2017-10-13 PT PT191890102T patent/PT3640251T/en unknown
- 2017-10-13 LT LT17783857T patent/LT3433256T/en unknown
- 2017-10-13 SG SG11201903182XA patent/SG11201903182XA/en unknown
- 2017-10-13 DK DK19189010.2T patent/DK3640251T3/en active
- 2017-10-13 CR CR20190204A patent/CR20190204A/en unknown
- 2017-10-13 SI SI201730111T patent/SI3433256T1/en unknown
- 2017-10-13 CN CN201780064567.7A patent/CN109843888B/en active Active
- 2017-10-13 PL PL19189010T patent/PL3640251T3/en unknown
- 2017-10-13 UA UAA201905126A patent/UA125824C2/en unknown
-
2018
- 2018-10-09 US US16/155,041 patent/US10590130B2/en active Active
-
2019
- 2019-02-01 ZA ZA2019/00694A patent/ZA201900694B/en unknown
- 2019-04-16 PH PH12019500830A patent/PH12019500830A1/en unknown
- 2019-04-18 CO CONC2019/0003950A patent/CO2019003950A2/en unknown
- 2019-04-18 CL CL2019001077A patent/CL2019001077A1/en unknown
- 2019-04-22 IL IL266245A patent/IL266245B/en active IP Right Grant
- 2019-04-23 EC ECSENADI201928657A patent/ECSP19028657A/en unknown
- 2019-04-23 DO DO2019000104A patent/DOP2019000104A/en unknown
- 2019-04-24 NI NI201900039A patent/NI201900039A/en unknown
- 2019-10-24 CY CY20191101110T patent/CY1122566T1/en unknown
-
2020
- 2020-01-28 US US16/774,268 patent/US10961241B2/en active Active
- 2020-07-30 JP JP2020129457A patent/JP6993477B2/en active Active
-
2021
- 2021-02-17 US US17/177,617 patent/US12077530B2/en active Active
-
2022
- 2022-02-23 CY CY20221100160T patent/CY1125292T1/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201903182XA (en) | 6,7,8,9-tetrahydro-3h-pyrazolo[4,3-f]isoquinoline derivatives useful in the treatment of cancer | |
| SG11201408324QA (en) | Pyridinone and pyridazinone derivatives | |
| SG11201901715UA (en) | Adenovirus armed with bispecific t cell engager (bite) | |
| SG11201900633XA (en) | Piperidine cxcr7 receptor modulators | |
| SG11201804915RA (en) | Methods for treating huntington's disease | |
| SG11201811414TA (en) | Heterocyclic compounds as immunomodulators | |
| SG11201906222WA (en) | Jak1 selective inhibitors | |
| SG11201909155VA (en) | Ask1 inhibitor compounds and uses thereof | |
| SG11201906386XA (en) | Combination therapy involving diaryl macrocyclic compounds | |
| SG11201906767XA (en) | Estrogen receptor modulators | |
| SG11201901558VA (en) | Pth compounds with low peak-to-trough ratios | |
| SG11201809751XA (en) | Egfr inhibitor compounds | |
| SG11201809499UA (en) | Processes for preparing phosphorodiamidate morpholino oligomers | |
| SG11201909807TA (en) | Methods of manufacturing of niraparib | |
| SG11201810965YA (en) | 1h-pyrazolo[4,3-b]pyridines as pde1 inhibitors | |
| SG11201901986SA (en) | Process for the manufacture of a solid pharmaceutical adminstration form | |
| SG11201810352XA (en) | New antibacterial compounds | |
| SG11201806393QA (en) | Use of gabaa receptor modulators for treatment of itch | |
| SG11201408641UA (en) | Phenoxyethyl piperidine compounds | |
| SG11201902949PA (en) | Pharmaceutical compositions and methods of treating cardiovascular diseases | |
| SG11201900361RA (en) | Methods of treating prostate cancer | |
| SG11201908065YA (en) | Deuterated imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer | |
| SG11201806424TA (en) | Therapeutic compounds | |
| SG11201901188VA (en) | Metal powder feedstocks for additive manufacturing, and system and methods for producing the same | |
| SG11201407345QA (en) | Pyrazole compounds as sglt1 inhibitors |